Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study

被引：0
|
作者：
Jin, Jie
Zhang, Yi
Zhang, Qike
Liu, Qingchi
Zhou, Hu
Gao, Sujun
Wang, Wei
Dang, Huibing
Chen, Yuqing
Wang, Jishi
Zhao, Peng
Yang, Haiping
Ma, Liangming
Zhao, Qingwei
Suo, Shanshan
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China
[3] Gansu Prov Hosp, Dept Hematol, Gansu, Peoples R China
[4] Hebei Med Univ, Dept Hematol, Hosp 1, Shijiazhuang, Peoples R China
[5] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Jilin Univ, Dept Hematol, Affiliated Hosp 1, Changchun, Peoples R China
[7] Qingdao Univ, Affiliated Hosp, Dept Hematol, Med Coll, Qingdao, Peoples R China
[8] First Affiliated Hosp, Dept Hematol, Nanyang Med Coll, Nanyang, Peoples R China
[9] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China
[10] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[11] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[12] Henan Univ Sci & Technol, Dept Hematol, Affiliated Hosp 1, Luoyang, Peoples R China
[13] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China
[14] Zhejiang Univ, Affiliated Hosp 1, Dept Clin Pharm, Sch Med, Hangzhou, Peoples R China
[15] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [41] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Johnston, P. B.
    Lewis, L. T.
    Rogerio, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study
    Shi, Yuan-Kai
    Hong, Xiao-Nan
    Yang, Jian-Liang
    Xu, Wei
    Huang, Hui-Qiang
    Xiao, Xiu-Bin
    Zhu, Jun
    Zhou, Dao-Bin
    Han, Xiao-Hong
    Wu, Jian-Qiu
    Zhang, Ming-Zhi
    Jin, Jie
    Ke, Xiao-Yan
    Li, Wei
    Wu, De-Pei
    Yang, Shen-Miao
    Du, Xin
    Jia, Yong-Qian
    Liu, Ai-Chun
    Liu, Dai-Hong
    Shen, Zhi-Xiang
    Zhang, Lian-Sheng
    James, Leonard
    Hellriegel, Edward
    CHINESE MEDICAL JOURNAL, 2021, 134 (11) : 1299 - 1309
  • [43] An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
    Izutsu, Koji
    Makita, Shinichi
    Nosaka, Kisato
    Yoshimitsu, Makoto
    Utsunomiya, Atae
    Kusumoto, Shigeru
    Morishima, Satoko
    Tsukasaki, Kunihiro
    Kawamata, Toyotaka
    Ono, Takaaki
    Rai, Shinya
    Katsuya, Hiroo
    Ishikawa, Jun
    Yamada, Hironori
    Kato, Kazunobu
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Adachi, Nobuaki
    Tobinai, Kensei
    Yonekura, Kentaro
    Ishitsuka, Kenji
    BLOOD, 2023, 141 (10) : 1159 - 1168
  • [44] A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer(RADIT)
    Fenner, Martin H.
    Dieing, Annetta
    Oechsle, Karin
    Hentrich, Marcus
    Gauler, Thomas Christoph
    Lorch, Anja
    Kopp, Hans-Georg
    Beyer, Joerg
    Bokemeyer, Carsten
    Gruenwald, Viktor
    Honecker, Friedmann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)
    Durrant, Simon
    Koren-Michowitz, Maya
    Lavie, David
    Martinez-Lopez, Joaquin
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    Stalbovskaya, Viktoriya
    Atienza, Edric
    Iommazzo, Dana
    Gopalakrishna, Prashanth
    Gisslinger, Heinz
    BLOOD, 2014, 124 (21)
  • [46] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [47] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Moshe Talpaz
    Susan Erickson-Viitanen
    Kevin Hou
    Solomon Hamburg
    Maria R. Baer
    Journal of Hematology & Oncology, 11
  • [48] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Talpaz, Moshe
    Erickson-Viitanen, Susan
    Hou, Kevin
    Hamburg, Solomon
    Baer, Maria R.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [49] A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Shah, Bijal D.
    Rozario, Nicole
    Turba, Elyce P.
    Bello, Celeste
    Chavez, Julio C.
    Sokol, Lubomir
    Brayer, Jason
    Lancet, Jeffrey E.
    BLOOD, 2021, 138
  • [50] Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study
    Xu, Wei
    Zhou, Keshu
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Ding, Kaiyang
    Zhou, Jianfeng
    Gao, Sujun
    Xu, Bing
    Zhu, Zunmin
    Liu, Ting
    Zhang, Huilai
    Hu, Jianda
    Ji, Chunyan
    Wang, Shunqing
    Xia, Zhongjun
    Wang, Xin
    Li, Yan
    Song, Yongping
    Ma, Shuo
    Tang, Xinran
    Zhang, Bin
    Li, Jianyong
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : 571 - 579
12345